Paper27936622
DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.
Stornetta A and 4 others. Chem Res Toxicol, 2017. Cited by 53 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine. Papers, record 27936622. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/27936622
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| DNA Adducts | Major topic |
| Animals | |
| Biomarkers | |
| Humans | |
| Hypoxia | |
| Nitrogen Mustard Compounds | |
| Oxidoreductases | |
| Platinum Compounds | |
| Precision Medicine | |
| Prodrugs |
Source PubMed
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA093373 | NCI NIH HHS | United States | P30CA093373 | PubMed and NIH | NIH RePORTER |
| 260341 | European Research Council | International | PubMed | PubMed | |
| P41 RR013461 | NCRR NIH HHS | United States | P41RR013461 | PubMed and NIH | NIH RePORTER |
| P41 GM103483 | NIGMS NIH HHS | United States | P41GM103483 | PubMed and NIH | NIH RePORTER |
| 680920 | European Research Council | International | PubMed | PubMed |
References180
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 9,510,497 | Cisplatin-DNA adducts and protein-bound platinum in blood of testicular cancer patients. | Anticancer Drugs | 1998 | https://conductscience.org/library/papers/9510497 | PubMed |
| 2 | 19,737,541 | ABT-737 overcomes Bcl-2 mediated resistance to doxorubicin-DNA adducts. | Biochem Pharmacol | 2010 | https://conductscience.org/library/papers/19737541 | PubMed |
| 3 | 3,324,117 | Metabolism and reactions of alkylating agents. | Pharmacol Ther | 1987 | https://conductscience.org/library/papers/3324117 | PubMed |
| 4 | 10,858,321 | Structure of adduct X, the last unknown of the six major DNA adducts of mitomycin C formed in EMT6 mouse mammary tumor cells. | Chem Res Toxicol | 2000 | https://conductscience.org/library/papers/10858321 | PubMed |
| 5 | 9,288,880 | Detection of DNA modifications by the 32P-postlabelling assay. | Mutat Res | 1997 | https://conductscience.org/library/papers/9288880 | PubMed |
| 6 | 24,254,606 | Ultrasensitive radioisotope, stable-isotope, and trace-element analysis in the biological sciences using tandem accelerator mass spectrometry. | Biol Trace Elem Res | 1987 | https://conductscience.org/library/papers/24254606 | PubMed |
| 7 | 9,400,943 | Platinum-DNA adduct formation in leucocytes of children in relation to pharmacokinetics after cisplatin and carboplatin therapy. | Br J Cancer | 1997 | https://conductscience.org/library/papers/9400943 | PubMed |
| 8 | 23,394,702 | Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer. | Bioanalysis | 2013 | https://conductscience.org/library/papers/23394702 | PubMed |
| 9 | 16,178,771 | Recent advances in understanding and exploiting the activation of anthracyclines by formaldehyde. | Curr Med Chem Anticancer Agents | 2005 | https://conductscience.org/library/papers/16178771 | PubMed |
| 10 | 11,476,483 | DNA minor-groove recognition by small molecules. | Nat Prod Rep | 2001 | https://conductscience.org/library/papers/11476483 | PubMed |
| 11 | 2,386,792 | Induction of stable transcriptional blockage sites by adriamycin: GpC specificity of apparent adriamycin-DNA adducts and dependence on iron(III) ions. | Biochemistry | 1990 | https://conductscience.org/library/papers/2386792 | PubMed |
| 12 | 7,192,601 | DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard. | Cancer Res | 1981 | https://conductscience.org/library/papers/7192601 | PubMed |
| 13 | 4,993,458 | Mitomycin derivatives. 2. Derivatives of decarbamoylmitosane and decarbamoylmitosene. | J Med Chem | 1971 | https://conductscience.org/library/papers/4993458 | PubMed |
| 14 | 21,793,181 | Formation of cyclophosphamide specific DNA adducts in hematological diseases. | Pediatr Blood Cancer | 2012 | https://conductscience.org/library/papers/21793181 | PubMed |
| 15 | 16,651,442 | Doxorubicin-DNA adducts induce a non-topoisomerase II-mediated form of cell death. | Cancer Res | 2006 | https://conductscience.org/library/papers/16651442 | PubMed |
| 16 | 21,028,869 | Gemcitabine causes minimal modulation of carboplatin-DNA monoadduct formation and repair in bladder cancer cells. | Chem Res Toxicol | 2010 | https://conductscience.org/library/papers/21028869 | PubMed |
| 17 | 17,606,726 | Mechanism of action and preclinical antitumor activity of the novel hypoxia-activated DNA cross-linking agent PR-104. | Clin Cancer Res | 2007 | https://conductscience.org/library/papers/17606726 | PubMed |
| 18 | 7,859,370 | Dose-response studies of MeIQx in rat liver and liver DNA at low doses. | Carcinogenesis | 1995 | https://conductscience.org/library/papers/7859370 | PubMed |
| 19 | 12,122,100 | An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. | J Natl Cancer Inst | 2002 | https://conductscience.org/library/papers/12122100 | PubMed |
| 20 | 10,064,864 | Correlation of DNA adduct levels with tumor incidence: carcinogenic potency of DNA adducts. | Mutat Res | 1999 | https://conductscience.org/library/papers/10064864 | PubMed |
Cited by31
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 53 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,592,091 | ADMET Profiling of the Metallodrugs: A Comparative Review of Platinum, Palladium, Gold, Ruthenium, Copper, and Zinc Anticancer Complexes. | Bioinorg Chem Appl | 2026 | https://conductscience.org/library/papers/42592091 | PubMed |
| 41,841,497 | Genome-wide CRISPR screens identify the EXO1-CAF-1 pathway suppressing R-loop-associated DNA damage. | Nucleic Acids Res | 2026 | https://conductscience.org/library/papers/41841497 | PubMed |
| 41,468,147 | The Unique Utility of Newborn Dried Blood Spots for Driving Discovery in Childhood Cancer Research. | Clin Chem | 2025 | https://conductscience.org/library/papers/41468147 | PubMed |
| 41,127,336 | Cisplatin resistance in head and neck squamous cell carcinoma is linked to DNA damage response and cell cycle arrest transcriptomics rather than poor drug uptake. | Cancer Drug Resist | 2025 | https://conductscience.org/library/papers/41127336 | PubMed |
| 40,767,287 | Vitamin C as a Cardioprotective Agent Against Doxorubicin-Induced Cardiotoxicity. | J Am Heart Assoc | 2025 | https://conductscience.org/library/papers/40767287 | PubMed |
| 40,663,054 | Evaluating Naphthalene-Modified Metallosalen Complexes as Anticancer Agents. | J Med Chem | 2025 | https://conductscience.org/library/papers/40663054 | PubMed |
| 40,513,340 | Treatment of human cells with the anti-cancer drug cisplatin results in the caspase-dependent release of adduct-containing cell-free DNA. | DNA Repair (Amst) | 2025 | https://conductscience.org/library/papers/40513340 | PubMed |
| 40,109,217 | DNA damage of peripheral blood lymphocytes as a dual biomarker: Diagnostic and treatment response in woman breast cancer patients. | Cancer Biomark | 2025 | https://conductscience.org/library/papers/40109217 | PubMed |
| 40,014,449 | Translesion-synthesis-mediated bypass of DNA lesions occurs predominantly behind replication forks restarted by PrimPol. | Cell Rep | 2025 | https://conductscience.org/library/papers/40014449 | PubMed |
| 38,231,175 | Mass Spectral Library for DNA Adductomics. | Chem Res Toxicol | 2024 | https://conductscience.org/library/papers/38231175 | PubMed |
| 37,490,747 | Liquid Chromatography-Mass Spectrometry Screening of Cyclophosphamide DNA Damage In Vitro and in Patients Undergoing Chemotherapy Treatment. | Chem Res Toxicol | 2023 | https://conductscience.org/library/papers/37490747 | PubMed |
| 37,375,269 | A Comparative Evaluation of the Photosensitizing Efficiency of Porphyrins, Chlorins and Isobacteriochlorins toward Melanoma Cancer Cells. | Molecules | 2023 | https://conductscience.org/library/papers/37375269 | PubMed |
| 36,820,303 | Characterization and quantitation of busulfan DNA adducts in the blood of patients receiving busulfan therapy. | Mol Ther Oncolytics | 2023 | https://conductscience.org/library/papers/36820303 | PubMed |
| 36,714,466 | Comparative analysis of chlorambucil-induced DNA lesion formation and repair in a spectrum of different human cell systems. | Toxicol Rep | 2023 | https://conductscience.org/library/papers/36714466 | PubMed |
| 36,694,906 | Bulky Adducts in Clustered DNA Lesions: Causes of Resistance to the NER System. | Acta Naturae | 2022 | https://conductscience.org/library/papers/36694906 | PubMed |
| 36,324,163 | Analysis of N7-(2-carbamoyl-2-hydroxyethyl)guanine in dried blood spot after food exposure by Ultra High Performance Liquid Chromatography-Tandem Mass Spectrometry. | BMC Chem | 2022 | https://conductscience.org/library/papers/36324163 | PubMed |
| 35,744,887 | Pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine Sulfonamides as Novel Potential Anticancer Agents: Cytotoxic and Genotoxic Activities In Vitro. | Molecules | 2022 | https://conductscience.org/library/papers/35744887 | PubMed |
| 34,876,121 | Identification of new candidate biomarkers to support doxorubicin treatments in canine cancer patients. | BMC Vet Res | 2021 | https://conductscience.org/library/papers/34876121 | PubMed |
| 34,576,304 | Applications of Adductomics in Chemically Induced Adverse Outcomes and Major Emphasis on DNA Adductomics: A Pathbreaking Tool in Biomedical Research. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34576304 | PubMed |
| 34,418,576 | Platinum-resistant ovarian cancer: From drug resistance mechanisms to liquid biopsy-based biomarkers for disease management. | Semin Cancer Biol | 2021 | https://conductscience.org/library/papers/34418576 | PubMed |
Genes14
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/27936622
GET https://conductscience.org/api/papers/v1/27936622/references?page=2